Compare BCRX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCRX | DAWN |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 1995 | 2021 |
| Metric | BCRX | DAWN |
|---|---|---|
| Price | $9.81 | $21.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $20.82 | ★ $24.43 |
| AVG Volume (30 Days) | ★ 5.9M | 2.8M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | $25,186,000.00 | ★ $158,182,000.00 |
| Revenue This Year | N/A | $55.03 |
| Revenue Next Year | $12.55 | $28.12 |
| P/E Ratio | $8.07 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $6.00 | $5.64 |
| 52 Week High | $11.31 | $21.47 |
| Indicator | BCRX | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 64.16 | 80.95 |
| Support Level | $7.85 | $10.30 |
| Resistance Level | $10.32 | N/A |
| Average True Range (ATR) | 0.56 | 0.05 |
| MACD | -0.05 | -0.36 |
| Stochastic Oscillator | 63.99 | 77.78 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.